Mueller, Sabrina http://orcid.org/0000-0003-4889-3058
Gottschalk, Fraence
Groth, Antje
Meeraus, Wilhelmine
Driessen, Maurice
Kohlmann, Thomas
Wilke, Thomas
Funding for this research was provided by:
GlaxoSmithKline
Article History
Received: 27 April 2018
Accepted: 15 August 2018
First Online: 30 August 2018
Ethics approval and consent to participate
: This analysis was based on studies conducted in accordance with the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practice guidelines and the principles of the Declaration of Helsinki. All participants provided written informed consent before inclusion in the analysis.
: Not applicable
: Maurice Driessen and Wilhelmine Meeraus are employees of GSK and hold stock in GSK. Sabrina Mueller, Fraence Gottschalk and Antje Groth participated in this study as a staff member of IPAM; IPAM work in this study was sponsored by GSK. No funding was provided to employees of IPAM for manuscript development. Thomas Wilke has received honoraria from several pharmaceutical/consultancy companies, for example, Novo Nordisk, Abbvie; Merck; GSK, BMS, LEO Pharma, AstraZeneca, Bayer, Boehringer Ingelheim, Pharmerit. Thomas Kohlmann received consultancy fees, project funding and reimbursement of travel costs from different pharmaceutical companies, for example, Bayer, Hexal, Lilly, Pfizer, Sanofi-Aventis.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.